• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors.针对人5型腺病毒抗原的预先存在的免疫对非人灵长类动物针对基于人源或黑猩猩源腺病毒载体的疫苗方案的免疫反应的影响。
J Virol. 2007 Jun;81(12):6594-604. doi: 10.1128/JVI.02497-06. Epub 2007 Apr 11.
2
Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens.腺病毒载体在非人灵长类动物中诱导的免疫反应:对初免-加强免疫方案的反应
J Immunol. 2009 May 15;182(10):6587-99. doi: 10.4049/jimmunol.0900317.
3
A CD46-binding chimpanzee adenovirus vector as a vaccine carrier.一种作为疫苗载体的结合CD46的黑猩猩腺病毒载体。
Mol Ther. 2007 Mar;15(3):608-17. doi: 10.1038/sj.mt.6300078. Epub 2007 Jan 16.
4
Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.使用重组黑猩猩腺病毒载体和佐剂化F4蛋白的异源初免-加强免疫方案在猕猴中引发多功能HIV-1特异性T细胞反应。
PLoS One. 2015 Apr 9;10(4):e0122835. doi: 10.1371/journal.pone.0122835. eCollection 2015.
5
Chimpanzee-origin adenovirus vectors as vaccine carriers.源自黑猩猩的腺病毒载体作为疫苗载体。
Gene Ther. 2006 Mar;13(5):421-9. doi: 10.1038/sj.gt.3302675.
6
Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.腺病毒载体疫苗:三种腺病毒科病毒载体的比较。
J Virol. 2010 Oct;84(20):10522-32. doi: 10.1128/JVI.00450-10. Epub 2010 Aug 4.
7
Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines.单周期复制型腺病毒疫苗产生的增强和持久的免疫应答。
J Virol. 2015 Jan;89(1):669-75. doi: 10.1128/JVI.02184-14. Epub 2014 Oct 29.
8
Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier.用腺病毒载体对小鼠进行口服疫苗接种不会因对疫苗载体的预先存在的免疫力而受到损害。
J Virol. 2003 Oct;77(20):10780-9. doi: 10.1128/jvi.77.20.10780-10789.2003.
9
Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors.在用腺病毒载体进行疫苗接种期间,树突状细胞的成熟而非CD8 + T细胞的诱导依赖于I型干扰素信号传导。
J Immunol. 2005 Nov 1;175(9):6032-41. doi: 10.4049/jimmunol.175.9.6032.
10
New insights on adenovirus as vaccine vectors.腺病毒作为疫苗载体的新见解。
Mol Ther. 2009 Aug;17(8):1333-9. doi: 10.1038/mt.2009.130. Epub 2009 Jun 9.

引用本文的文献

1
Single-Dose Intranasal or Intramuscular Administration of Simian Adenovirus-Based H1N1 Vaccine Induces a Robust Humoral Response and Complete Protection in Mice.基于猿猴腺病毒的H1N1疫苗单剂量鼻内或肌肉注射给药可在小鼠中诱导强烈的体液反应并提供完全保护。
Viruses. 2025 Aug 5;17(8):1085. doi: 10.3390/v17081085.
2
A single-dose intranasal immunization with a novel bat influenza A virus-vectored MERS vaccine provides effective protection against lethal MERS-CoV challenge.用一种新型甲型蝙蝠流感病毒载体中东呼吸综合征疫苗进行单剂量鼻内免疫可有效抵御致死性中东呼吸综合征冠状病毒攻击。
mBio. 2025 Jun 30:e0110725. doi: 10.1128/mbio.01107-25.
3
Advancing ORFV-Based Therapeutics to the Clinical Stage.将基于羊口疮病毒的疗法推进到临床阶段。
Rev Med Virol. 2025 May;35(3):e70038. doi: 10.1002/rmv.70038.
4
Immunogenicity and protective efficacy of a multi-antigenic adenovirus-based vaccine candidate against .一种基于多抗原腺病毒的候选疫苗针对……的免疫原性和保护效力
Front Microbiol. 2025 Jan 24;16:1492268. doi: 10.3389/fmicb.2025.1492268. eCollection 2025.
5
Emerging Gene-editing nano-therapeutics for Cancer.新兴的用于癌症治疗的基因编辑纳米疗法
Heliyon. 2024 Oct 20;10(21):e39323. doi: 10.1016/j.heliyon.2024.e39323. eCollection 2024 Nov 15.
6
Development of mRNA rabies vaccines.mRNA 狂犬病疫苗的研发。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2382499. doi: 10.1080/21645515.2024.2382499. Epub 2024 Jul 28.
7
Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV.既往ChAdOx1新冠疫苗免疫对T细胞对ChAdOx1乙肝疫苗反应的影响。
Vaccines (Basel). 2024 Jun 9;12(6):644. doi: 10.3390/vaccines12060644.
8
SARS-CoV-2: A Glance at the Innate Immune Response Elicited by Infection and Vaccination.严重急性呼吸综合征冠状病毒2(SARS-CoV-2):感染和疫苗接种引发的固有免疫反应一瞥
Antibodies (Basel). 2024 Feb 8;13(1):13. doi: 10.3390/antib13010013.
9
Recent Advances in Therapeutic Approaches Against Ebola Virus Infection.埃博拉病毒感染治疗方法的最新进展。
Recent Adv Antiinfect Drug Discov. 2024;19(4):276-299. doi: 10.2174/0127724344267452231206061944.
10
Aerosol Inhalation of Chimpanzee Adenovirus Vectors (ChAd68) Expressing Ancestral or Omicron BA.1 Stabilized Pre-Fusion Spike Glycoproteins Protects Non-Human Primates against SARS-CoV-2 Infection.吸入表达原始或奥密克戎BA.1稳定前融合刺突糖蛋白的黑猩猩腺病毒载体(ChAd68)可保护非人灵长类动物免受SARS-CoV-2感染。
Vaccines (Basel). 2023 Aug 28;11(9):1427. doi: 10.3390/vaccines11091427.

本文引用的文献

1
A CD46-binding chimpanzee adenovirus vector as a vaccine carrier.一种作为疫苗载体的结合CD46的黑猩猩腺病毒载体。
Mol Ther. 2007 Mar;15(3):608-17. doi: 10.1038/sj.mt.6300078. Epub 2007 Jan 16.
2
Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa.撒哈拉以南非洲地区人类体内的黑猩猩腺病毒抗体
Emerg Infect Dis. 2006 Oct;12(10):1596-9. doi: 10.3201/eid1210.060078.
3
Generation of an adenoviral vaccine vector based on simian adenovirus 21.基于猿猴腺病毒21型的腺病毒疫苗载体的构建
J Gen Virol. 2006 Sep;87(Pt 9):2477-2485. doi: 10.1099/vir.0.81989-0.
4
Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults.1型人类免疫缺陷病毒pGA2/JS2质粒DNA初免载体疫苗在未感染1型艾滋病毒的成年人中的卓越安全性和耐受性。
AIDS Res Hum Retroviruses. 2006 Jul;22(7):678-83. doi: 10.1089/aid.2006.22.678.
5
Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys.接种疫苗的恒河猴感染猴免疫缺陷病毒后,CD4+ 中央记忆性T细胞的保存与存活。
Science. 2006 Jun 9;312(5779):1530-3. doi: 10.1126/science.1124226.
6
Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.通过使用表达与CD8 + T细胞表位偶联的HIV-1 Gag的DNA和改良安卡拉痘苗病毒载体疫苗的初免-加强方案,在健康受试者中诱导能够增殖的多功能1型人类免疫缺陷病毒(HIV-1)特异性T细胞。
J Virol. 2006 May;80(10):4717-28. doi: 10.1128/JVI.80.10.4717-4728.2006.
7
Immunity's yin and yang. A successful vaccine must first avoid being eliminated by pre-existing immunity before it can promote a protective immune response.免疫的阴阳平衡。一种成功的疫苗必须首先避免被预先存在的免疫所清除,然后才能促进保护性免疫反应。
IAVI Rep. 2006 Jan-Feb;10(1):1-5.
8
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.六邻体嵌合5型腺病毒载体可规避预先存在的抗载体免疫。
Nature. 2006 May 11;441(7090):239-43. doi: 10.1038/nature04721. Epub 2006 Apr 16.
9
Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults.用于健康志愿者和HIV感染成年人的HIV脂肽疫苗的临床安全性。
AIDS. 2006 Apr 24;20(7):1039-49. doi: 10.1097/01.aids.0000222077.68243.22.
10
De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses.源自腺病毒载体的马尔堡病毒抗原的从头合成可诱导强烈的体液免疫和细胞免疫反应。
Vaccine. 2006 Apr 5;24(15):2975-86. doi: 10.1016/j.vaccine.2005.11.046. Epub 2005 Dec 9.

针对人5型腺病毒抗原的预先存在的免疫对非人灵长类动物针对基于人源或黑猩猩源腺病毒载体的疫苗方案的免疫反应的影响。

Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors.

作者信息

McCoy Kimberly, Tatsis Nia, Korioth-Schmitz Birgit, Lasaro Marcio O, Hensley Scott E, Lin Shih-Wen, Li Yan, Giles-Davis Wynetta, Cun Ann, Zhou Dongming, Xiang Zhiquan, Letvin Norman L, Ertl Hildegund C J

机构信息

The Wistar Institute, 3601 Spruce St., Philadelphia PA 19104, USA.

出版信息

J Virol. 2007 Jun;81(12):6594-604. doi: 10.1128/JVI.02497-06. Epub 2007 Apr 11.

DOI:10.1128/JVI.02497-06
PMID:17428852
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1900096/
Abstract

In this study we compared a prime-boost regimen with two serologically distinct replication-defective adenovirus (Ad) vectors derived from chimpanzee serotypes C68 and C1 expressing Gag, Pol, gp140, and Nef of human immunodeficiency virus type 1 with a regimen in which replication-defective Ad vectors of the human serotype 5 (AdHu5) were given twice. Experiments were conducted in rhesus macaques that had or had not been preexposed to antigens of AdHu5. There was no significant difference in T-cell responses tested from peripheral blood of the different groups, although responses were overall highest in nonpreexposed animals immunized with the chimpanzee Ad vectors. Preexisting immunity to AdHu5 completely inhibited induction of transgene product-specific antibodies by the AdHu5 vectors without affecting antibody responses to the chimpanzee vectors. Upon euthanasia, T-cell responses were tested from a number of tissues. Preexisting immunity to AdHu5, commonly found in humans, changed the homing pattern of vaccine-induced T cells. In AdHu5-preexposed animals vaccinated with the chimpanzee Ad vectors, frequencies of transgene-specific T cells were higher in spleens than in blood, and in most preexposed animals vaccinated either with AdHu5 vectors or chimpanzee adenovirus vectors, frequencies of such T cells were exceptionally high in livers. The latter results indicate that analysis of T-cell responses solely from blood mononuclear cells of vaccine recipients may not suffice to compare the potencies of different vaccine regimens.

摘要

在本研究中,我们将一种初免-加强免疫方案与另一种方案进行了比较。前一种方案使用了两种血清学上不同的、源自黑猩猩血清型C68和C1的复制缺陷型腺病毒(Ad)载体,它们表达1型人类免疫缺陷病毒的Gag、Pol、gp140和Nef;后一种方案是给予两次人类血清型5(AdHu5)的复制缺陷型Ad载体。实验在曾接触或未接触过AdHu5抗原的恒河猴中进行。不同组外周血检测的T细胞反应没有显著差异,不过在用黑猩猩Ad载体免疫的未接触过抗原的动物中反应总体最高。对AdHu5的预先存在的免疫力完全抑制了AdHu5载体诱导的转基因产物特异性抗体,而不影响对黑猩猩载体的抗体反应。安乐死时,从多个组织检测了T细胞反应。在人类中常见的对AdHu5的预先存在的免疫力改变了疫苗诱导的T细胞的归巢模式。在用黑猩猩Ad载体接种疫苗的预先接触过AdHu5的动物中,转基因特异性T细胞在脾脏中的频率高于血液中的频率,并且在大多数用AdHu5载体或黑猩猩腺病毒载体接种疫苗的预先接触过抗原的动物中,此类T细胞在肝脏中的频率异常高。后一结果表明,仅分析疫苗接受者血液单核细胞中的T细胞反应可能不足以比较不同疫苗方案的效力。